ZNF641 Inhibitors
Chemical inhibitors of ZNF641 function through a variety of mechanisms to impede its activity within cells. Staurosporine and Bisindolylmaleimide I target protein kinases, with the former inhibiting a broad spectrum of these enzymes and the latter specifically targeting protein kinase C (PKC). By blocking these kinases, they prevent the phosphorylation that is crucial for the activation and proper function of ZNF641. Inhibition of phosphorylation by these compounds leads to a reduction in ZNF641's ability to adopt the necessary conformation for DNA binding and interaction with other proteins, thus impeding its function.
LY294002 and Wortmannin are both inhibitors of phosphatidylinositol 3-kinase (PI3K), a key component of the PI3K-Akt signaling pathway. This pathway is implicated in various cellular functions, and its inhibition can alter the signaling that modulates the activity of ZNF641. By curtailing the PI3K-Akt pathway, LY294002 and Wortmannin can lead to a decrease in the post-translational modifications of ZNF641 that are crucial for its activity. Additionally, Trichostatin A and C646 interfere with the acetylation of histones, a process that is important for the chromatin structure that ZNF641 may interact with. Trichostatin A prevents deacetylation by inhibiting histone deacetylases, while C646 inhibits the histone acetyltransferase p300. These alterations in histone acetylation can disrupt the chromatin context necessary for ZNF641 to exert its functions. RG108 and 5-Azacytidine act upon DNA methylation; RG108 by directly inhibiting DNA methyltransferases and 5-Azacytidine by incorporating into DNA and RNA, which affects the methylation status. These changes can impede ZNF641's interaction with methylated DNA sequences, thus inhibiting its regulatory capabilities. Lastly, PD98059, SP600125, SB203580, and U0126 target various kinases within the MAPK signaling pathways. PD98059 and U0126 specifically inhibit MEK1/2, SP600125 inhibits JNK, and SB203580 targets p38 MAP Kinase. By obstructing these pathways, they can decrease the regulation of ZNF641 activity as these pathways may influence the phosphorylation state and interaction of ZNF641 with other regulatory proteins.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits protein kinases that are involved in the activation of ZNF641. By inhibiting these kinases, Staurosporine prevents the phosphorylation of ZNF641, which is necessary for its functional conformation and ability to bind DNA, thereby inhibiting ZNF641's activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can inhibit the PI3K-Akt signaling pathway. Since this pathway is involved in the cellular processes that may include the functional regulation of ZNF641, LY294002 inhibits this pathway, potentially reducing the functional activity of ZNF641 by limiting its activation signals. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that prevents the PI3K-mediated activation of downstream targets involved in the regulation of ZNF641. Inhibition of this pathway by Wortmannin can lead to a decrease in ZNF641 activity by affecting its post-translational modifications and interaction with other proteins. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is an inhibitor of histone deacetylases. If ZNF641 requires a specific chromatin context for its activity, the alteration of acetylation status by Trichostatin A can lead to an inhibition of ZNF641's DNA binding and regulatory functions. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $265.00 $944.00 | 5 | |
C646 is a selective inhibitor of the histone acetyltransferase p300. Inhibition of p300 can result in reduced histone acetylation affecting the chromatin interactions of ZNF641, potentially leading to an inhibition of its DNA-binding activity and subsequent regulatory functions. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
RG108 is a DNA methyltransferase inhibitor. By altering the methylation status of DNA, RG108 may disrupt the methyl-DNA binding domain-dependent interactions of ZNF641, leading to an inhibition of its ability to regulate gene expression. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine incorporates into DNA and RNA and inhibits DNA methyltransferases. This action can impede ZNF641's interaction with methylated DNA sequences, potentially inhibiting its regulatory functions. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits MEK1/2. As MEK1/2 are upstream regulators in the MAPK/ERK pathway, which may influence ZNF641's activity, inhibition of this pathway by PD98059 can result in decreased functional activity of ZNF641. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. JNK pathway is involved in the regulation of transcription factors and other proteins that may interact with ZNF641. Inhibition by SP600125 can impede these interactions, leading to a decrease in ZNF641's activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP Kinase. By inhibiting p38 MAP Kinase, SB203580 can affect the regulatory networks that control the activity and function of ZNF641, resulting in functional inhibition of ZNF641. | ||||||